Evaluating AI Penny Stocks to Buy: Three Candidates for Speculative Investors

The artificial intelligence sector continues to generate significant investment interest, with AI penny stocks to buy representing one avenue for investors seeking substantial upside exposure. These ultra-small cap equities operate at the intersection of massive opportunity and considerable risk. For investors willing to tolerate extreme volatility, the reward potential can be substantial. However, this strategy demands discipline: expect that roughly 80% of positions may underperform, while the remaining 20% could deliver outsized returns. Success requires ruthlessly cutting losses on poor performers while allowing winning positions to compound.

Rekor Systems: AI Infrastructure for Smart Transportation Networks

Headquartered in the infrastructure software sector, Rekor Systems (NASDAQ: REKR) operates as a compelling yet unpredictable candidate among AI penny stocks to buy. The company specializes in providing intelligence solutions for transportation, public safety, and urban mobility across domestic and international markets. Its flagship product, Rekor One, leverages artificial intelligence to deliver real-time roadway insights and traffic intelligence capabilities.

The stock’s performance tells a volatile story. REKR experienced a significant 41% drawdown from recent peaks, yet achieved an 84% gain over a 52-week period—illustrating the extreme price swings characteristic of this asset class. Currently trading below $2 per share, technical analysts speculate that a move toward the $4 level could replicate this performance trajectory. This narrative receives support from analyst projections that had anticipated revenue of approximately $66 million for the fiscal period, representing projected growth of 89% relative to the prior year’s $35 million. Subsequent year estimates suggested revenues could climb to $88.74 million, implying an additional 34% expansion.

Inuvo: Real-Time AI-Driven Advertising Solutions

Inuvo (NYSE American: INUV) exemplifies the dual nature of AI penny stocks to buy—substantial risk paired with a defensible business thesis. Operating within digital communications and advertising services, Inuvo develops technology solutions for brands, advertising agencies, and major media consolidators. The company’s competitive advantage centers on real-time optimization of advertising purchase and placement decisions.

Central to its offering is IntentKey, an AI-based platform designed to identify consumer purchase intent across mobile and desktop channels while accommodating multiple creative formats. As consumer discretionary spending faces headwinds, solutions enabling precision targeting become increasingly valuable. Historical analyst projections had estimated annual revenue reaching $94.54 million, reflecting approximately 28% growth from the prior year’s $73.91 million. Subsequent-year forecasts suggested potential revenue expansion to $113.43 million, implying roughly 20% year-over-year growth. For investors demonstrating conviction and patience, INUV represents a consideration within the AI penny stocks to buy category.

Predictive Oncology: Bridging AI and Drug Discovery

Predictive Oncology (NASDAQ: POAI), based in Eagan, Minnesota, pursues a specialized mission within medical devices and supplies—specifically, applying artificial intelligence to oncology drug discovery. The company’s differentiation lies in its ability to accelerate molecular development by integrating human biological diversity earlier in the discovery pipeline. This process is enabled through the pairing of AI algorithms with an extensive biobank containing approximately 150,000 tumor samples.

This opportunity carries exceptional risk. Since the beginning of the prior trading year, POAI shares declined more than 63%, creating justified hesitation regarding entry points. Historically, securities experiencing such magnitude of decline frequently continue depreciating. However, the intersection of artificial intelligence and pharmaceutical development presents an intriguing long-term narrative. Prior-year revenue totaled approximately $1.78 million, up modestly from the preceding year’s $1.5 million. The investment thesis here centers less on current financials than on forward market dynamics. Industry research had projected the AI-driven drug discovery market could expand at a compound annual growth rate of 40.2%, positioning POAI as fundamentally speculative.

Making the Investment Decision

Selecting AI penny stocks to buy requires acknowledging the inherent tradeoffs. These securities are not suitable for conservative portfolios. The three candidates outlined above—Rekor Systems, Inuvo, and Predictive Oncology—each operate in rapidly evolving AI applications with meaningful revenue trajectories. Yet each carries corresponding downside risks. Investors considering this strategy should size positions appropriately, maintain strict stop-loss discipline, and recognize that losses will likely outnumber winners. For those meeting these prerequisites, AI penny stocks to buy can offer portfolio-enhancing exposure to emerging artificial intelligence applications across infrastructure, advertising, and healthcare sectors.